RAJKUMAR MANICKAM | Molecular Biology | Molecular Biology Scientist Award

Published on by Molecular Biologist

Assist. Prof. Dr. RAJKUMAR MANICKAM | Molecular Biology | Molecular Biology Scientist Award 

Assistant Professor | Karpagam Academy of Higher Education | India

Assist. Prof. Dr. Manickam Rajkumar is an accomplished scientist recognized for his work in nanotechnology, molecular biology, and biomedical applications. His research spans biopolymer-based nanocomposites, green nanotechnology, drug delivery systems, and therapeutic strategies for neurodegenerative diseases, cancer, and microbial infections. With strong interdisciplinary training and extensive experience in in vitro, in vivo, and in silico methodologies, he contributes to advanced material synthesis, biomolecular characterization, behavioural neuroscience, and molecular diagnostics. His studies have identified nanocomposites with significant antioxidant capacity, modulation of toxic protein aggregation, and cognitive enhancement potential in disease models. His research interests include computational biology, biomedical coatings, metal oxide nanostructures, metabolic disorder therapeutics, and marine bioactive materials. He has produced impactful scientific contributions reflected in 325 citations, 232 citing documents, 27 publications, and an h-index of 11. His work has earned competitive fellowships and multiple best presentation awards at major scientific conferences, underscoring his influence as a growing researcher in biomedical innovation.

Profiles: Scopus | ORCID | Google Scholar
Featured Publications

Biosynthesis of cerium oxide nanoparticles. Biomedical Materials & Devices.

Review on green synthesis of nanoparticles. Biomedical Materials & Devices.

Biosynthesis of chitosan–TiO₂ nanoparticles. Inorganic Chemistry Communications.

CuO nanoparticles for colon cancer therapy. Journal of Cluster Science.

NanoMarine therapeutics for colon cancer. Frontiers in Genetics.

Eco-friendly synthesis of ZnO nanoparticles. Inorganic Chemistry Communications.

Sooyoung Kim | Molecular Biology | Editorial Board Member

Published on by Molecular Biologist

Dr. Sooyoung Kim | Molecular Biology | Editorial Board Member

Industry | US Neurophth Therapeutics (Ex-) | United States

Soo-Young Kim is an accomplished researcher specializing in retinal biology, neurodegeneration, and therapeutic development for ocular diseases. He holds a PhD in Medicine from Korea University and has extensive experience across academia and industry, including positions at UC Irvine, Neurophth Therapeutics, ExosomePlus, Johns Hopkins Wilmer Eye Institute, and the National Eye Institute. His research focuses on retinal development, age-related macular degeneration, and neovascularization, with significant contributions to understanding photoreceptor synapse formation, retinal degeneration models, and inflammatory pathways in pathological neovascularization. Kim has authored numerous publications in high-impact journals, advancing both basic science and translational applications in ophthalmology. His work combines molecular, cellular, and whole-mount techniques to elucidate disease mechanisms and support drug evaluation, reflecting a strong commitment to bridging experimental research with therapeutic innovation.

Profile: ORCID

Featured Publications

Kim, S.-Y., Park, C. H., Moon, B.-H., & Seabold, G. K. Murine Retina Outer Plexiform Layer Development and Transcriptome Analysis of Pre-Synapses in Photoreceptors. Life, 14(9), 1103.

Moon, B.-H., Kim, Y., & Kim, S.-Y. Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment. International Journal of Molecular Sciences, 24(16), 13004.

Kim, S.-Y., & Qian, H. Comparison between sodium iodate and lipid peroxide murine models of age-related macular degeneration for drug evaluation—a narrative review. Annals of Eye Science, 7, Article 25.

Kim, S.-Y., Zhao, Y., Kim, H.-L., Oh, Y., & Xu, Q. Sodium iodate-induced retina degeneration observed in non-separate sclerochoroid/retina pigment epithelium/retina whole mounts. Annals of Eye Science, 7, Article 27.

Lee, S.-J., & Kim, S.-Y. Mouse Sclerochoroid/RPE/Retina posterior eyeball staining and Whole Mounts. BIO-PROTOCOL, 11(15), e3872.

Kim, S.-Y. Inflammatory pathways in pathological neovascularization in retina and choroid: a narrative review on the inflammatory drug target molecules in retinal and choroidal neovascularization. Annals of Eye Science, 6, Article 4.

Georges Nemer | Molecular Biology | Editorial Board Member

Published on by Molecular Biologist

Prof. Georges Nemer | Molecular Biology | Editorial Board Member 

Professor | Hamad Bin Khalifa University | Qatar

Dr. Georges Nemer is a prominent molecular cardiology and biomedical research expert whose work spans cardiac development, congenital heart defects, transcriptional regulation, and translational molecular biology. His research has uncovered key mechanisms governing cardiogenesis, including defining the role of the T-box transcription factor Tbx5 in heart formation and disease, demonstrating how GATA-4 overexpression enhances cardiogenesis in embryonic stem cells, and revealing the cooperative regulation of myocardial gene expression by GATA-4 and GATA-6. Dr. Nemer has also contributed to clinical genetics through the identification of novel GATA4 mutations associated with Tetralogy of Fallot, supporting improved understanding of congenital heart malformations. Beyond cardiology, his scholarship extends to dermatological science, elucidating molecular pathways and clinical applications of retinoids, and to computational biochemistry through work on protein-ligand docking using AutoDock for targets such as BACE1. His interdisciplinary portfolio reflects a commitment to bridging basic science and clinical relevance, advancing knowledge across cardiac biology, human genetics, molecular therapeutics, and biomedical modeling.

Profile: Google Scholar

Featured Publications

Bruneau, B. G., Nemer, G., Schmitt, J. P., Charron, F., Robitaille, L., Caron, S., …
(2001). A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell, 106(6), 709–721.

Grépin, C., Nemer, G., & Nemer, M. (1997). Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor. Development, 124(12), 2387–2395.

Charron, F., Paradis, P., Bronchain, O., Nemer, G., & Nemer, M. (1999). Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Molecular and Cellular Biology, 19(6), 4355–4365.

Khalil, S., Bardawil, T., Stephan, C., Darwiche, N., Abbas, O., Kibbi, A. G., …
(2017). Retinoids: A journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. Journal of Dermatological Treatment, 28(8), 684–696.

Nemer, G., Fadlalah, F., Usta, J., Nemer, M., Dbaibo, G., Obeid, M., & Bitar, F. (2006). A novel mutation in the GATA4 gene in patients with Tetralogy of Fallot. Human Mutation, 27(3), 293–294.

El-Hachem, N., Haibe-Kains, B., Khalil, A., Kobeissy, F. H., & Nemer, G. (Year unavailable). AutoDock and AutoDockTools for protein-ligand docking: Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a case study. Neuroproteomics: Methods and Protocols, 391–403.

Rouba NASREDDINE | Molecular Diagnostics | Women Researcher Award

Published on by Molecular Biologist

Assoc. Prof. Dr. Rouba NASREDDINE | Molecular Diagnostics | Women Researcher Award 

Doctorate | ICOA | France

Dr. Rouba Nasreddine is an accomplished Lebanese-French scientist and Associate Professor at the University of Orléans, France, specializing in analytical chemistry and environmental analysis. She is a member of the Analytical Strategies, Affinities and Bioactives (SAAB) research team at the Institute of Organic and Analytical Chemistry (ICOA), where her work bridges analytical innovation and environmental sustainability through advanced detection methods for bioaerosols and volatile organic compounds. Her research contributions extend across chromatography, spectroscopy, and microscale thermophoresis, with a focus on enzyme dynamics and molecular affinities in complex environments. She has published 19 scientific documents, cited 327 times across 283 sources, and holds an h-index of 11, reflecting her growing impact in the field. Dr. Nasreddine’s interdisciplinary collaborations and teaching at the University Institute of Technology of Orléans continue to inspire innovation in analytical science and sustainable chemistry.

Profile: Scopus | ORCID

Featured Publications

Nasreddine, R., et al. (2025). Molecules, 30, 4008. [Cited by 12 articles]

Kharrat, O., et al. (2025). PNAS, 122, e2415524122. [Cited by 24 articles]

Kharrat, O., et al. (2025). J. Biol. Chem., 301, 110587. [Cited by 16 articles]

Chartier, S., et al. (2025). Analytica Chimica Acta, 1360, 344145. [Cited by 8 articles]

Quinty, V., et al. (2023). Food Bioscience, 55, 103069. [Cited by 20 articles]

Laura Estrada | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Prof. Laura Estrada | Molecular Biology | Best Researcher Award 

Researcher | Physics department University of Buenos Aires | Argentina

Prof. Laura Cecilia Estrada is a physicist, educator, and researcher whose work bridges advanced optical microscopy, nanotechnology, and interdisciplinary biophysics. She serves as Adjunct Professor at the Department of Physics, University of Buenos Aires and Independent Researcher at CONICET, where she leads pioneering investigations in fluorescence spectroscopy, nanoimaging, and virus-host interactions. Estrada completed her academic training in physics at the University of Buenos Aires, earning her Licenciatura and Ph.D. with highest distinction, and later expanded her expertise as a postdoctoral researcher and group leader at the University of California, Irvine. Her research focuses on fluorescence-based techniques, single-particle tracking, and nano-optics applied to both fundamental physics and biomedical sciences, with special emphasis on dengue and Zika virus proteins. Alongside her scientific contributions, she has played key leadership roles in professional societies and gender equity initiatives. Her work has been recognized nationally and internationally, including awards from the International Commission for Optics, the Biophysical Society, and Argentina’s INNOVAR program. She has supervised numerous theses, mentored young scientists, and fostered international collaborations. With 35 publications, 325 citations, and an h-index of 9, Estrada exemplifies scientific rigor, innovation, and social commitment in advancing both knowledge and equity.

Profile: Scopus

Featured Publications

Sallaberry, I., & Estrada, L. Unraveling viral protein-host membrane interaction for dengue and Zika. Biophysical Journal.

Leon, A., Sallaberry, I., Estrada, L., & Scorticati, C. Non-synonymous SNPs within GPM6A impair hippocampal neuron development. Biochimica et Biophysica Acta, 1872(3). Cited by 2.

Salzman, V., & Estrada, L. Replicative lifespan determination of yeast using microfluidic chip. Biology Open, 13(11). Cited by 5.

Gaggioli, E., Estrada, L., & Bruno, O. Boundary layer structures in transport theory. Physical Review E, 110. Cited by 3.

Philipp, N., Gratton, E., & Estrada, L. Protein-membrane interaction via radial FCS. Methods and Applications in Fluorescence, 11(4). Cited by 12.

Gabriel, M., & Estrada, L. Dengue Virus Capsid Protein Dynamics in live cells. Scientific Reports, 10. Cited by 45.

Maria Camprubi Robles | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Maria Camprubi Robles | Molecular Biology | Best Researcher Award 

Research Scientist | Abbott Laboratories | Spain

Dr. Maria Camprubi is a highly accomplished Research Scientist with over a decade of dedicated service at Abbott Nutrition, specializing in molecular and cellular biology. With strong expertise in nutritional science, she has significantly contributed to the development of innovative products that address sarcopenia, chronic disease, and malnutrition across Europe, the Middle East, and Africa. She holds a Ph.D. in Molecular and Cellular Biology, where she built a strong foundation in cellular processes and metabolic regulation. Her academic training provided the expertise to bridge laboratory research with clinical nutrition, forming the cornerstone of her impactful scientific career.  Dr. Camprubi has worked at Abbott in the R&D department, leading projects that focus on the nutritional management of vulnerable populations. Her experience spans cross-functional collaborations, clinical trials, and translating research into practical solutions that improve health outcomes globally. Her research interests focus on nutrition metabolism to support muscle health, healthy aging, oncology, and diabetes. She aims to create evidence-based interventions that help prevent muscle decline, enhance recovery during chronic illnesses, and promote long-term well-being in aging populations. Dr. Camprubi has been recognized within Abbott for her leadership in advancing nutritional innovation. Her commitment to applying molecular and clinical insights to product development has positioned her as a leading scientist driving transformative changes in health and nutrition. She has authored impactful publications in peer-reviewed journals, contributing knowledge on nutritional metabolism, sarcopenia, and disease-related malnutrition. Her scientific contributions have achieved 1,276 citations by 1,194 documents, with 24 published documents and an h-index of 17, reflecting her influence in the scientific community and the value of her contributions to global health research.

Profile: Scopus

Featured Publications

A prospective, observational study of the effect of a high-calorie, high-protein oral nutritional supplement with HMB in an old and malnourished or at-risk-of-malnutrition population with hip fractures: A FracNut study. Nutrients, 16(8)

The vicious cycle of type 2 diabetes mellitus and skeletal muscle atrophy: Clinical, biochemical, and nutritional bases. Nutrients, 16(1), 172

Shangze Li | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Assoc. Prof. Dr. Shangze Li | Molecular Biology | Best Researcher Award 

Assistant to the Dean | Chongqing University | China

Dr. Shangze Li (Ph.D., Associate Professor, Ph.D. Supervisor) is a distinguished researcher in the fields of antiviral innate immune signaling, inflammatory responses, and tumor biology. He is based at the School of Medicine, Chongqing University, where he leads a research group and supervises doctoral students. His work integrates advanced genetic engineering technologies such as gene knockout, knock-in approaches, and disease models to investigate the molecular basis of immune regulation and cancer development. Dr. Li has published extensively in leading international journals including Nature Communications, Cell Death and Differentiation, Cancer Research, Oncogene, and Cancer Letters, with several contributions featured in Nature Index journals. His studies have been widely cited, reflecting both scientific impact and relevance to the global biomedical community. In addition to research, he is actively involved in teaching, mentoring, editorial service, and academic leadership, contributing to the advancement of both education and medical research.

Professional Profile

Scopus

ORCID

Google Scholar

Education 

Dr. Li completed his doctoral degree in Cell Biology at Wuhan University, where he focused on the molecular mechanisms that link immune regulation to tumorigenesis. Prior to his doctoral training, he pursued two undergraduate degrees, one in Bioengineering from the Chengdu University of Technology and another in Business Administration from the University of Electronic Science and Technology of China. This unique combination of scientific and managerial education provided him with both technical expertise and leadership skills. After completing his doctorate, Dr. Li undertook postdoctoral training at the Feinberg School of Medicine, Northwestern University, where he worked on projects exploring molecular oncology, innate immunity, and translational approaches in cancer research. His diverse academic background, spanning engineering, business, molecular biology, and medical research, has prepared him to integrate interdisciplinary knowledge in his career. This foundation continues to guide his role as a scientist, supervisor, and contributor to medical and biological sciences.

Experience 

Dr. Li began his professional research career at the Feinberg School of Medicine, Northwestern University, where he served as a postdoctoral researcher in molecular oncology and immune regulation. Following this period of international training, he returned to China and accepted an appointment at Zhongnan Hospital of Wuhan University and the College of Life Sciences, where he contributed to teaching and research in biomedical sciences. He later joined the School of Medicine at Chongqing University as a faculty member, where he was subsequently promoted to Associate Professor and Ph.D. Supervisor. In this role, he leads a laboratory focused on investigating immune signaling and cancer development. In addition to his research and teaching, Dr. Li has taken on administrative responsibilities, serving as Assistant to the Dean and Deputy Director of Shared Core Facilities for Medical Research. His experience reflects a career that balances leadership, education, and internationally recognized scientific research.

Research Interests 

Dr. Li’s research centers on the molecular mechanisms of innate immune signaling, inflammation, and tumor biology. His work explores how signaling pathways regulate immune homeostasis and contribute to tumor initiation and progression. He employs genetically modified cell lines, CRISPR-based technologies, and animal models to examine the functional roles of key genes in these processes. His studies often focus on ubiquitination and deubiquitination pathways, NF-κB signaling, and the crosstalk between cellular metabolism and cell death. This approach provides critical insights into how molecular dysregulation drives oncogenesis and resistance to therapy. His research also emphasizes translational applications, identifying potential biomarkers and therapeutic strategies that may guide novel approaches in cancer treatment and immune-related diseases. By integrating molecular biology, immunology, and cancer research, Dr. Li contributes to advancing both fundamental scientific knowledge and practical innovations for improving health outcomes.

Awards 

Dr. Li’s research achievements have been recognized through broad citation and publication in top international journals. His scholarly contributions have been acknowledged in Nature Communications, Molecular Cancer, Cancer Research, and other leading journals, with some articles featured as cover stories in Nature Index publications. His body of work has earned substantial recognition in the scientific community, reflected in a strong citation record and consistent invitations to review for leading journals. He has also served as Guest Editor for Vaccines and as a reviewer for the National Natural Science Foundation of China, underscoring his role as a trusted scientific evaluator. Beyond research output, Dr. Li has contributed actively to professional organizations, including serving as a council member of the Chongqing Association of Young Scientists and participating in national academic initiatives. His record demonstrates recognition for both scholarly impact and professional service, positioning him as a strong candidate for scientific honors.

Top Noted Publications 

Dr. Li has authored more than forty peer-reviewed publications, including a substantial number as first or corresponding author. His research has appeared in high-impact journals such as Nature Communications, Molecular Cancer, Oncogene, Cancer Research, and Cancer Letters. Selected publications include Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression in Cells, CLK2 mediates NF-κB regulation in Nature Communications, Crosstalk between metabolism and cell death in tumorigenesis in Molecular Cancer, USP14 promotes colorectal cancer progression in Cell Death & Disease, and MAPK signaling and drug resistance in prostate cancer in Cancer Research. These publications reflect his long-term focus on the molecular basis of immune regulation and cancer biology. His findings have been widely cited and have advanced understanding of tumorigenesis, therapeutic resistance, and immunoregulation. Collectively, his research portfolio highlights his contributions to both fundamental science and translational medicine, strengthening his standing as an influential scholar in the field of biomedical research.

Title: Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression
Journal: Cells
Year: 2024
Cited by: 15+

Title: CLK2 mediates IkappaBalpha-independent NF-κB regulation
Journal: Nature Communications
Year: 2024
Cited by: 30+

Title: Crosstalk between metabolism and cell death in tumorigenesis
Journal:  Molecular Cancer
Year: 2024
Cited by: 40+

Title: USP14 promotes colorectal cancer progression
Journal: Cell Death & Disease
Year: 2023
Cited by: 25+

Title: Activation of MAPK by CXCR7 causes drug resistance
Journal: Cancer Research
Year: 2019
Cited by: 200+

Conclusion

Dr. Shangze Li is a highly suitable candidate for the Best Researcher Award. His outstanding research achievements, strong academic influence, and balanced contributions to teaching, mentorship, and professional service highlight his excellence as a scholar. With continued focus on international collaboration, high-impact publications, and global leadership roles, he is exceptionally well-positioned to be recognized with this award.

Heng Zhang | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Heng Zhang | Molecular Biology | Best Researcher Award 

Lecturer | Nankai University | China

Dr. Zhang Heng is a Lecturer in Pharmacology at Nankai University, specializing in investigating the molecular mechanisms underlying malignant tumor progression and developing innovative drug therapies. He earned his B.S., M.S., and Ph.D. in Pharmaceutical Sciences from Nankai University, completing his doctoral studies with high distinction. Since joining the faculty as a lecturer, he has been actively engaged in teaching, mentoring, and advancing cutting-edge cancer research. Dr. Zhang has published multiple high-impact papers in prestigious SCI-indexed journals, including Molecular Cell, Signal Transduction and Targeted Therapy, and Advanced Materials. His scholarly contributions include original research on extrachromosomal DNA, tumor stem cell propagation, and nanomedicine-based immunotherapy. He also holds four patent applications and has received several top academic and innovation awards. Through his research and academic leadership, Dr. Zhang continues to make significant contributions toward improving the understanding of cancer biology and developing novel therapeutic strategies for clinical application.

Professional Profile

ORCID

Education

Dr. Zhang Heng pursued his higher education entirely at Nankai University, a leading institution in China recognized for excellence in pharmaceutical research. He began his academic journey with a Bachelor of Science degree in Pharmaceutical Sciences, where he built a strong foundation in pharmacology, molecular biology, and medicinal chemistry. Continuing at Nankai, he completed his Master of Science degree, focusing on the molecular biology of tumors and early drug discovery methodologies. His master’s research involved extensive laboratory experiments, including molecular cloning, protein analysis, and tumor cell line studies. Dr. Zhang then earned his Ph.D. in Pharmaceutical Sciences, conducting advanced research on the molecular mechanisms driving cancer progression and identifying new targets for therapeutic intervention. His doctoral studies resulted in multiple publications in internationally recognized journals. This academic path, marked by consistent excellence and research productivity, has equipped him with the knowledge and skills essential for his role as an independent researcher and educator.

Experience

Following the completion of his doctoral studies, Dr. Zhang Heng was appointed Lecturer at the College of Pharmacy, Nankai University. In this role, he has been responsible for delivering lectures in pharmacology, supervising undergraduate and graduate students, and leading research initiatives in molecular oncology. He has designed and managed multiple research projects, often collaborating with interdisciplinary teams, and has successfully bridged fundamental science with translational medicine. His experience encompasses conducting high-level molecular biology research, managing laboratory operations, and contributing to scientific publications as both first and corresponding author. He has filed patents for innovative drug delivery systems and tumor immunotherapies, demonstrating the applied impact of his work. Beyond laboratory research, Dr. Zhang has participated in national-level innovation competitions and academic conferences, presenting his findings to peers and experts in the field. His experience reflects a balance of teaching excellence, research innovation, and contribution to the broader scientific community.

Research Interest

Dr. Zhang Heng’s research interests lie at the intersection of cancer biology, molecular pharmacology, and drug innovation. He investigates the fundamental mechanisms that drive the malignant progression of tumors, including the role of extrachromosomal DNA, R-loop dynamics, and vasculogenic mimicry. His work also explores how specific proteins and epigenetic factors regulate tumor growth, immune evasion, and stem cell maintenance. In addition to basic research, Dr. Zhang focuses on developing new therapeutic strategies, such as tumor-targeted nanomedicines, biomimetic exosomes, and in situ tumor vaccines. He aims to integrate these novel approaches into translational medicine frameworks, ultimately leading to more effective, personalized cancer treatments. His interdisciplinary methodology combines molecular biology, pharmacology, nanotechnology, and immunotherapy, with the overarching goal of creating clinically applicable solutions for some of the most aggressive and treatment-resistant cancers. This research focus reflects both scientific curiosity and a commitment to advancing healthcare outcomes.

Award

Dr. Zhang Heng has been recognized for his outstanding research achievements, innovative contributions, and academic excellence through multiple prestigious awards. He received the Second Prize of the Tianjin Science and Technology Progress Award, which acknowledges impactful scientific advancements with practical applications. His innovative work in drug development and cancer therapy earned him the Gold Award at the China International “Internet Plus” Innovation and Entrepreneurship Competition. In recognition of his leadership, scientific merit, and contributions to society, he was awarded the Tianjin May Fourth Youth Medal. While a student, Dr. Zhang received the Zhou Enlai Scholarship, the highest honor granted by Nankai University, and was named Nankai University Student of the Year. These distinctions highlight not only his research excellence but also his dedication to innovation, community engagement, and the advancement of pharmacological sciences on both a national and international level.

Top Noted Publication

Dr. Zhang Heng has authored a series of impactful publications in high-ranking scientific journals, contributing significantly to the fields of molecular oncology and drug development. His research outputs span mechanistic cancer biology studies, novel therapeutic approaches, and the application of nanotechnology in tumor immunotherapy. These publications have been cited in multiple peer-reviewed articles, demonstrating their influence within the global scientific community. His work continues to inform and inspire ongoing research in cancer treatment innovation.

Publications list (single-line prompt):

Title: Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1–Lig3–PARylation complex
Journal: Molecular Cell
Year: 2025

Title: MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells
Journal: Signal Transduction and Targeted Therapy
Year: 2021

Title: Biomimetic Immunosuppressive Exosomes that Inhibit Cytokine Storms Contribute to the Alleviation of Sepsis
Journal: Advanced Materials
Year: 2022

Title: Magnetic sculpture-like tumor cell vaccines enable targeted in situ immune activation and potent antitumor effects
Journal: Theranostics
Year: 2025

Title: Vitamin D binding protein (VDBP) hijacks Twist1 to inhibit vasculogenic mimicry in hepatocellular carcinoma
Journal: Theranostics
Year: 2024

Conclusion

Dr. Zhang Heng is a highly suitable candidate for the Research for Best Researcher Award. His combination of scientific excellence, innovation, and societal impact aligns well with the award’s criteria. With continued growth in global collaboration and academic leadership, he has the potential to become a leading figure in pharmacology and cancer research worldwide.

 

Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award

Published on by Molecular Biologist

Dr. Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award 

Scientific Research Lead | Memorial Sloan Kettering Cancer Center | United States

Dr. Ingrid Tatiana Erazo is a distinguished cancer researcher and Scientific Research Lead at Memorial Sloan Kettering Cancer Center (MSKCC) with extensive experience in translational oncology. She earned her PhD Summa Cum Laude in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, where she pioneered research on the ERK5 signaling pathway. Her early postdoctoral work led to the discovery of the mechanism of action for ABTL-0812, an autophagy-inducing anticancer agent now in Phase III clinical trials. Over the past decade at MSKCC, she has advanced understanding of PRMT5 inhibition, therapeutic resistance, and biomarker development for precision oncology. She currently leads initiatives integrating liquid biopsy diagnostics for early cancer detection and is spearheading global health equity programs, including the creation of Brazil’s first national referral network for cancer clinical trials. Her work bridges molecular discoveries with clinical application, driving advancements in both targeted therapies and diagnostic tools.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Dr. Erazo earned her PhD in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, graduating Summa Cum Laude. Her doctoral research focused on dissecting the ERK5 signaling pathway and its role in cancer cell proliferation and survival. She used Tandem Affinity Purification to map ERK5’s interactome, uncovering novel noncanonical mechanisms and post-translational modifications such as SUMOylation that opened new therapeutic opportunities. Collaborating with Dana-Farber Cancer Institute at Harvard, she co-developed potent and selective ERK5 inhibitors, providing valuable pharmacological tools for cancer research. Her academic training combined molecular biology with translational oncology, giving her a unique foundation to move seamlessly from bench research to clinical applications. She also pursued advanced training in biomarker discovery and molecular diagnostics, enabling her to contribute to projects that merge fundamental discoveries with practical solutions for cancer detection, prognosis, and treatment optimization in a variety of clinical contexts.

Experience

Dr. Erazo’s professional career spans more than 20 completed research projects and leadership in multiple ongoing studies, covering molecular oncology, biomarker discovery, and therapeutic resistance. At MSKCC, she elucidated the mechanism of action of PRMT5 inhibitors and identified MUSASHI-2 as a driver of drug resistance in hematologic malignancies, leading to innovative combination therapy strategies. She developed liquid biopsy-based diagnostics for aggressive prostate cancers and integrated proteomic biomarkers into clinical research pipelines. In her earlier postdoctoral role at Ability Pharmaceuticals, she was instrumental in advancing ABTL-0812 to clinical trials by defining its mechanism and identifying relevant biomarkers. She has partnered with global pharmaceutical and biotech companies, including GlaxoSmithKline, Biodesix Inc., and Guardant Health. Her work also extends to global health initiatives, such as establishing Brazil’s first national referral network for cancer clinical trials with molecular profiling, aiming to address disparities in cancer care and ensure equitable access to precision oncology.

Research Interest

Dr. Erazo’s research focuses on cancer biology, mechanisms of drug resistance, biomarker discovery, and precision oncology. She has a particular interest in hematological malignancies and aggressive solid tumors where therapeutic resistance significantly impacts patient outcomes. Her work applies genome-wide CRISPR synthetic lethal screening, proteomics, and high-throughput drug screening to identify cancer vulnerabilities and inform new treatment strategies. She is advancing diagnostic methods through liquid biopsy technology, enabling early and non-invasive tumor detection and monitoring, with a focus on neuroendocrine prostate cancer. Dr. Erazo also addresses global health inequities by developing clinical trial networks in underrepresented regions and incorporating genetic ancestry into study designs to improve population-specific therapeutic approaches. By combining basic molecular research with translational and clinical applications, she aims to ensure that future cancer therapies and diagnostics are effective across diverse populations and accessible beyond high-resource healthcare settings.

Awards

Dr. Erazo’s scientific achievements have positioned her as a leader in translational cancer research and a nominee for the Molecular Biology Contribution Award. She is recognized for her groundbreaking work on ERK5 signaling, the clinical biomarker development for ABTL-0812, and the identification of MUSASHI-2 as a therapeutic resistance driver. Her contributions to liquid biopsy-based proteomic biomarkers for detecting lineage transformation in prostate cancer have advanced early diagnostic capabilities in precision oncology. She has also been a driving force behind the establishment of Brazil’s first national clinical trial referral network, demonstrating a strong commitment to global health equity. Her work, cited extensively in scientific literature, reflects both scientific rigor and real-world clinical impact. These accomplishments highlight her role as both a laboratory innovator and a global health strategist, whose research has shaped cancer treatment strategies and advanced diagnostic development on an international scale.

Top Noted Publications

Dr. Erazo has authored over 20 peer-reviewed articles in high-impact journals, including Annals of Oncology, Nature Communications, Autophagy, and Clinical Cancer Research. Her research spans mechanistic cancer biology, drug development, and biomarker-driven clinical applications. She has contributed to significant discoveries such as mapping the ERK5 interactome, elucidating the mechanism of action for ABTL-0812, and identifying resistance biomarkers for hematological malignancies. Her publications often emerge from collaborative projects that integrate molecular biology, pharmacology, and clinical trial data, reflecting her multidisciplinary approach to advancing oncology research. The high citation count of her work underscores its influence and the adoption of her findings by researchers and clinicians worldwide. Her studies have informed clinical trial design, therapeutic development, and diagnostic tool implementation, bridging the gap between basic science and patient-centered outcomes in cancer care.

Selected Publications (Single-Line Format)

Title: Erazo T, et al. The new antitumor drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels
Journal: Nature Communications
Cited by 312

Title: Erazo T, et al. Inhibition of PRMT5 in lymphomas overcomes therapeutic resistance via MUSASHI-2 modulation
Journal: Clinical Cancer Research
Cited by 145

Title: Erazo T, et al. ERK5 kinase activity-independent functions in cancer: implications for drug development
Journal: Autophagy
Cited by 110

Title: Erazo T, et al. Blood-based proteomic biomarkers for early detection of lineage plasticity in prostate cancer
Journal: Annals of Oncology
Cited by 35

Title: Erazo T, et al. High-throughput screening of FDA-approved drugs for novel therapeutic combinations in lymphoma
Journal: Molecular Oncology
Cited by 28

Conclusion

Dr. Ingrid Tatiana Erazo’s pioneering research, translational breakthroughs, and commitment to equitable precision oncology position her as an outstanding candidate for the Research for Molecular Biology Contribution Award. Her work exemplifies how rigorous molecular biology can directly shape novel therapeutics, diagnostics, and healthcare systems globally. Awarding her would recognize not only her individual achievements but also her vision for transforming cancer care through innovation and inclusivity.

 

King-cheong LAM | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. King-cheong LAM | Molecular Biology | Best Researcher Award

Senior Lecturer, at The School of Professional Education and Executive Development (SPEED), The Hong Kong Polytechnic University, Hong Kong.

Dr. LAM King-cheong Antony is a seasoned academic currently serving as a Senior Lecturer in the Division of Science, Engineering and Health Studies at the College of Professional and Continuing Education (CPCE), The Hong Kong Polytechnic University. With a rich interdisciplinary background in physics and engineering education, Dr. Lam has consistently contributed to innovative teaching methods and research initiatives. His career journey from a secondary school teacher to a respected university lecturer is marked by dedication to student development, academic leadership, and community outreach. 📘 His roles as Programme Leader and Co-Investigator in prestigious funded projects reflect his commitment to applied research and educational advancement. Through his work in nanotechnology, sustainable energy, and smart sensor systems, Dr. Lam exemplifies a professional devoted to shaping the future of science education and technology for sustainable urban living. 🌱

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Antony Lam’s academic path is built on a solid foundation in science and education. 🎓 He earned his Doctor of Philosophy from The Hong Kong Polytechnic University in 2017, where he focused on gas sensing materials using graphene-based composites. Prior to that, he completed his Master of Philosophy (2008) and Bachelor of Science in Physics (2005) at The University of Hong Kong, establishing his grounding in physical sciences. Recognizing the importance of pedagogy in science, he also pursued a Postgraduate Diploma in Education from The University of Hong Kong in 2010, equipping himself with the skills to bridge research and teaching. This rare blend of scientific rigor and educational expertise empowers him to mentor students and lead cross-disciplinary research with confidence. 🧠 His training has laid the foundation for a career devoted to both scientific discovery and academic development.

💼 Experience

Dr. Lam’s professional career spans across secondary and tertiary education sectors. 🏫 From 2007 to 2012, he began his journey as a science teacher at Heung To Secondary School (TKO), where he nurtured young minds with enthusiasm for physics. In 2018, he transitioned to higher education as a Lecturer at CPCE, The Hong Kong Polytechnic University, and was promoted to Senior Lecturer in 2024. Over the years, Dr. Lam has taken on several key academic leadership roles, including Programme Leader for Associate in Engineering and Higher Diploma in Aircraft Services Engineering, and Assistant Programme Leader for the BEng (Hons) in Mechanical Engineering. 💼 These positions not only reflect his pedagogical expertise but also his capability in curriculum innovation and academic governance. Dr. Lam’s dedication to bridging practical engineering with academic training is central to his career mission of advancing applied science education. ⚙️

🔬 Research Interests

Dr. Lam’s research interests lie at the intersection of nanotechnology, green energy, sustainable materials, and smart sensing systems. 🌍 His work explores the fabrication of advanced materials such as tin-based perovskites, graphene composites, and aluminum-ion batteries to enhance energy efficiency and sensor capabilities. A significant part of his research addresses real-world sustainability challenges—ranging from developing natural fiber/concrete composites for eco-friendly buildings to ionic-liquid-based gas sensors for smart cities. 🏙️ He is also actively investigating thermal and mechanical properties of biomaterials, including mycelium-based composites for biomedical applications. His interdisciplinary approach combines physics, chemistry, and engineering to produce applicable technologies for energy and healthcare sectors. Through multiple funded projects and international conferences, Dr. Lam has established himself as a researcher committed to translational science for societal impact. 🌱

🏅 Awards

Dr. Lam’s research excellence has earned him both institutional recognition and competitive external grants. 🏆 In 2023, he received the KML Third Prize (HK$200,000) from the Koo Meng Li and Koo Mi Wen Na Charitable Foundation Limited for his project on natural fiber/concrete composites for sustainable buildings. He has been a Principal Investigator and Co-Investigator in numerous high-impact projects, including a nearly HK$1 million RGC-funded project on mycelium-based insoles for diabetic care. 💰 These awards and grants highlight his innovative work in sustainable technology and material science. Dr. Lam’s recognition not only reflects his technical acumen but also his leadership in building collaborative, real-world solutions. His consistent involvement in cutting-edge research underscores his role as a forward-thinking academic in science and engineering education. 🧪

📚 Top Noted Publications

Dr. Lam has contributed to a number of peer-reviewed journals and conferences in the fields of materials science, physics, and engineering education. His most cited works involve graphene-based sensors, perovskite solar cells, and AR learning systems. 📖 His publication list includes:

1. Ahmed, S. B., Kan, H. W., Lam, K. C., & Yip, C. T. (2025)

Title: Charge-induced isomerization in alkyl imine molecular motors: a reduced energy barrier approach
Journal: RSC Advances, 15(10), 8053–8059.

  • Focus: Investigates charge-induced isomerization mechanisms in alkyl imine-based molecular motors.

  • Contribution: Proposes a novel approach to reducing the energy barrier for directional motion.

  • Significance: Offers insights into molecular machines and nanoscale actuation.

2. Wang, Y. D., et al., incl. Lam, K. C. (2024)

Title: Direct manipulation of diffusion in colloidal glasses via quasi-particle-like defects
Journal: Physical Review E, 110(6), 064603.

  • Focus: Explores defect-driven dynamics in colloidal glasses.

  • Contribution: Demonstrates how quasi-particle-like defects can directly control diffusion.

  • Significance: Advances fundamental understanding of amorphous materials and soft matter physics.

3. Li, K. C., Lam, K. C., et al. (2024)

Title: Designing ultrathin ferromagnetic nanowires for Majorana mode studies
Journal: Results in Physics, Article ID 107322.

  • Focus: Investigates ferromagnetic nanowires for potential topological quantum computing applications.

  • Contribution: Proposes new nanowire designs optimized for stabilizing Majorana zero modes.

  • Significance: Supports progress in solid-state quantum computation.

4. Lo, K., Ng, J., Chau, & Lam, A. (2023)

Title: AR-based mobile learning for electrical fundamentals
Journal: Journal of Online Engineering Education, 14(2), 01–12.

  • Focus: Combines augmented reality (AR) with mobile learning for engineering education.

  • Contribution: Assesses effectiveness of interactive AR tools for teaching basic electrical concepts.

  • Significance: Enhances engagement and learning outcomes in STEM education.

5. Lam, K. C., Huang, B., & Shi, S. Q. (2017)

Title: Room-temperature methane gas sensing with graphene-SnO₂
Journal: Journal of Materials Chemistry A, 5, 11131–11142.

  • Focus: Develops graphene-SnO₂ composites for methane sensing at ambient temperature.

  • Contribution: Demonstrates high sensitivity and fast response/recovery cycles.

  • Significance: Highly cited (over 300 citations on Google Scholar)—a foundational paper in gas sensor development using nanomaterials.

Conclusion

Dr. LAM King-cheong Antony is highly suitable for consideration for a Best Researcher Award. His record showcases a consistent trajectory of impactful, interdisciplinary research, successful funding, academic service, and innovation. With growing momentum in both fundamental and applied sciences, and continued leadership within CPCE, he exemplifies the qualities of a committed and forward-thinking researcher. Acknowledging him with such an award would recognize not only his past achievements but also encourage his ongoing contributions to science and engineering.